Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 formulations, including semaglutide and tirzepatide-based treatments, for ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

In adults with obesity but not diabetes, tirzepatide leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight ...

Recently, the United States has witnessed an intense legal and commercial confrontation between major pharmaceutical ...

TORONTO, May 13, 2025 /CNW/ - Lilly Canada is pleased to announce that Mounjaro ® KwikPen ® (tirzepatide injection) is now available in Canada in all doses, offering a convenient treatment ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release ...